Subsequently treatment with PARP inhibitors was found to result in synthetic lethality in BRCA1/2 mutant tumors [152, 153] and the PARP inhibitors olaparib and talazoparib are now FDA-approved as monotherapy treatments in BRCA1/2 mutant advanced breast cancer [154, 155]. Here, PARP1 is linked to breast carcinoma.